5 Citations (Scopus)

Abstract

Sustained-release sodium fluoride (SR-NaF or Neosten(TM), Mission Pharmacal Company, San Antonio, TX) opens an exciting new approach in the management of postmenopausal osteoporosis. Unlike available drugs that are antiresorptive agents [1], SR-NaF is a formation-stimulating agent [2]. Thus, SR-NaF has a greater potential for augmenting spinal bone mass and inhibiting spinal fractures than antiresorptive agents. However, the response to treatment is not due to the properties of SR-NaF alone, but also to the particular treatment format [3]. To capture the maximum benefits of SR-NaF, it must be provided intermittently with continuous calcium citrate (or Citracal®, Mission Pharmacal Company, San Antonio, TX) supplementation. In this review, the unique properties of SRNaF and features of the treatment format will be described first. Laboratory and clinical results of treatment then will be provided.

Original languageEnglish (US)
Pages (from-to)15-20
Number of pages6
JournalEndocrinologist
Volume8
Issue number1
StatePublished - Jan 1998

Fingerprint

Bone Density Conservation Agents
Fluorides
Osteoporosis
Calcium Citrate
Spinal Fractures
Sodium Fluoride
Postmenopausal Osteoporosis
Bone and Bones
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Endocrinology

Cite this

Update of fluoride in the treatment of osteoporosis. / Pak, Charles Y C; Sakhaee, Khashayar; Rubin, Craig; Rao, Sudhaker.

In: Endocrinologist, Vol. 8, No. 1, 01.1998, p. 15-20.

Research output: Contribution to journalArticle

@article{93d566f1322c41d1aeeabfe996413fcd,
title = "Update of fluoride in the treatment of osteoporosis",
abstract = "Sustained-release sodium fluoride (SR-NaF or Neosten(TM), Mission Pharmacal Company, San Antonio, TX) opens an exciting new approach in the management of postmenopausal osteoporosis. Unlike available drugs that are antiresorptive agents [1], SR-NaF is a formation-stimulating agent [2]. Thus, SR-NaF has a greater potential for augmenting spinal bone mass and inhibiting spinal fractures than antiresorptive agents. However, the response to treatment is not due to the properties of SR-NaF alone, but also to the particular treatment format [3]. To capture the maximum benefits of SR-NaF, it must be provided intermittently with continuous calcium citrate (or Citracal{\circledR}, Mission Pharmacal Company, San Antonio, TX) supplementation. In this review, the unique properties of SRNaF and features of the treatment format will be described first. Laboratory and clinical results of treatment then will be provided.",
author = "Pak, {Charles Y C} and Khashayar Sakhaee and Craig Rubin and Sudhaker Rao",
year = "1998",
month = "1",
language = "English (US)",
volume = "8",
pages = "15--20",
journal = "Endocrinologist",
issn = "1051-2144",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Update of fluoride in the treatment of osteoporosis

AU - Pak, Charles Y C

AU - Sakhaee, Khashayar

AU - Rubin, Craig

AU - Rao, Sudhaker

PY - 1998/1

Y1 - 1998/1

N2 - Sustained-release sodium fluoride (SR-NaF or Neosten(TM), Mission Pharmacal Company, San Antonio, TX) opens an exciting new approach in the management of postmenopausal osteoporosis. Unlike available drugs that are antiresorptive agents [1], SR-NaF is a formation-stimulating agent [2]. Thus, SR-NaF has a greater potential for augmenting spinal bone mass and inhibiting spinal fractures than antiresorptive agents. However, the response to treatment is not due to the properties of SR-NaF alone, but also to the particular treatment format [3]. To capture the maximum benefits of SR-NaF, it must be provided intermittently with continuous calcium citrate (or Citracal®, Mission Pharmacal Company, San Antonio, TX) supplementation. In this review, the unique properties of SRNaF and features of the treatment format will be described first. Laboratory and clinical results of treatment then will be provided.

AB - Sustained-release sodium fluoride (SR-NaF or Neosten(TM), Mission Pharmacal Company, San Antonio, TX) opens an exciting new approach in the management of postmenopausal osteoporosis. Unlike available drugs that are antiresorptive agents [1], SR-NaF is a formation-stimulating agent [2]. Thus, SR-NaF has a greater potential for augmenting spinal bone mass and inhibiting spinal fractures than antiresorptive agents. However, the response to treatment is not due to the properties of SR-NaF alone, but also to the particular treatment format [3]. To capture the maximum benefits of SR-NaF, it must be provided intermittently with continuous calcium citrate (or Citracal®, Mission Pharmacal Company, San Antonio, TX) supplementation. In this review, the unique properties of SRNaF and features of the treatment format will be described first. Laboratory and clinical results of treatment then will be provided.

UR - http://www.scopus.com/inward/record.url?scp=0031892712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031892712&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0031892712

VL - 8

SP - 15

EP - 20

JO - Endocrinologist

JF - Endocrinologist

SN - 1051-2144

IS - 1

ER -